Skip to content

Effect of Esketamine on Acute Moderate-to-Severe Pain After Thoracoscopic Lung Surgery: A Multicenter, Prospective, Double-Blind, Randomized Controlled Trial

Effect of Esketamine on Acute Moderate-to-Severe Pain After Thoracoscopic Lung Surgery: A Multicenter, Prospective, Double-Blind, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123948
Enrollment
Unknown
Registered
2026-05-04
Start date
2026-05-04
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Esketamine Group:Esketamine injection (2ml/50mg), continuous infusion at 0.3 mg/kg/h for 1 hour starting after intubation
Saline Control Group:Isotonic saline of equivalent volume, continuous infusion at 0.3 mg/kg/h for 1 hour starting after intubation

Sponsors

Shanghai Pulmonary Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age 18 years or older; 2. American Society of Anesthesiologists (ASA) physical status I to III; 3. Scheduled for elective thoracoscopic pulmonary resection under general anesthesia, with an expected surgical duration of at least 1 hour; 4. Provision of written informed consent.

Exclusion criteria

Exclusion criteria: 1. Participation in another interventional study; 2. Use of antidepressants, alcohol abuse, chronic opioid use, or long-term use of analgesics; 3. History of significant psychiatric disease, including cognitive dysfunction, bipolar disorder, or intellectual disability; 4. Inability to understand and complete pain scoring; 5. Severe hepatic or renal impairment (Child-Pugh Class C liver function or eGFR < 30 mL/min/1.73m^2); 6. Unstable angina, acute coronary syndrome or coronary revascularization within the previous 6 months, intracranial hypertension, or elevated intraocular pressure; 7. Uncontrolled hypertension; 8. Known allergy to esketamine, ketamine, or related derivatives; 9. Preoperative chest pain; 10. Body mass index greater than or equal to 35 kg/m^2; 11. Pregnancy or breastfeeding.

Design outcomes

Primary

MeasureTime frame
Incidence of acute moderate-to-severe pain within 24 hours after surgery;

Secondary

MeasureTime frame
Total opioid consumption within 48 hours after surgery;Incidence of moderate-to-severe pain within 48 hours after surgery;Numeric Rating Scale (NRS) pain score at rest;Pain score during coughing or movement;Rescue analgesia rate;Quality of recovery score-15 at 24h, 48h after surgery;Incidence of PONV;Length of postoperative hospital stay;

Countries

China

Contacts

Public ContactLü Xin

Shanghai Pulmonary Hospital

xinlvg@126.com+86 21 6511 5006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026